December 8, 2021
Terumo Aortic today announced the launch and first commercial case of the Aortic Balloon in the United States. The device assists physicians in the expansion of the aorta when using TREO and RELAY stent-grafts in endovascular aortic repair.
Complementing our market leading product range of surgical and endovascular grafts, the Aortic Balloon is a low profile device with 10 F and offers exceptional inflation control and the broadest balloon diameter range, up to 50mm.
The first commercial use of the product was undertaken by Dr Siddharth Patel, Vascular Surgeon, Northside Vascular Surgery, Atlanta, GA during an implantation of a TREO abdominal stent-graft. Dr Patel commented: "The Aortic Balloon performed very well, with good inflation control, and rapid inflation and deflation. Also, its low profile gave me the ability to utilize the 13F leg extension detachable sheath of Treo for stent-graft remodelling without exchanging sheaths."
Paul Kuznik, President of Terumo Aortic North America commented: "We are delighted to bring this low-profile balloon to the market and strengthen our credentials as a one-stop shop for aortic solutions."
This device is integral to Terumo Aortic's innovative portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.
At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be
personalised for every patient. We are further complementing our implantable device
portfolio through the development of digital technologies.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Corporate Communication Dept., Terumo Corporation
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.